C130026I21Rik Activators are a diverse set of chemical compounds that indirectly bolster the functional activity of C130026I21Rik through their targeted effects on various signaling pathways. Forskolin, by raising cAMP levels, and Isoproterenol, acting as a beta-adrenergic agonist, indirectly amplify C130026I21Rik activity by fostering cAMP-dependent pathways. Similarly, Dibutyryl-cAMP, as a direct cAMP analog, enhances C130026I21Rik by acting on these same pathways. Phorbol 12-myristate 13-acetate (PMA) and Staurosporine function through modulation of protein kinase C and broad kinase activity respectively, potentially influencing the phosphorylation status of proteins that directly or indirectly activate C130026I21Rik. Moreover, Epigallocatechin gallate (EGCG) and Genistein serve as tyrosine kinase inhibitors, which could relieve the competitive inhibition on signaling pathways, thereby enhancing the pathways in which C130026I21Rik is involved. Sphingosine-1-phosphate further complements this activation by engaging with G protein-coupled receptors to potentiate downstream signaling conducive to C130026I21Rik's functional activity.
The remaining compounds contribute to the activation of C130026I21Rik by modulating intracellular calcium levels and the PI3K/Akt pathway, which is known to interact with processes that C130026I21Rik may regulate. Ionomycin and A23187, both calcium ionophores, raise intracellular calcium levels, potentially enabling calcium-dependent signaling pathways that lead to the functional activation of C130026I21Rik. LY294002, as a PI3K inhibitor, and U0126, as a MEK inhibitor, may indirectly enhance C130026I21Rik activity by attenuating the PI3K/Akt and MAPK pathways, respectively, allowing for the engagement of alternative signaling routes that could activate C130026I21Rik. Collectively, these activators work through distinct yet complementary mechanisms to increase the functional activity of C130026I21Rik without the need for direct binding or upregulation, supporting the protein's role in cellular signaling networks.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which may phosphorylate downstream proteins involved in the signaling pathways that lead to the functional activity of C130026I21Rik. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin acts as a calcium ionophore, raising intracellular calcium levels and potentially influencing calcium-dependent signaling pathways that C130026I21Rik may be part of. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a tyrosine kinase inhibitor that may reduce activity of certain tyrosine kinases, potentially enhancing signaling pathways in which C130026I21Rik is involved through reduced competitive inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor which may shift the activity of downstream signaling towards pathways that could enhance the activity of C130026I21Rik. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor, which may lead to the activation of alternative pathways that indirectly enhance the activity of C130026I21Rik by reducing the MAPK pathway activity. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187, a calcium ionophore, increases intracellular calcium levels, potentially enhancing C130026I21Rik's activity by activating calcium-dependent signaling pathways. | ||||||
Calcium dibutyryladenosine cyclophosphate | 362-74-3 | sc-482205 | 25 mg | $147.00 | ||
Dibutyryl-cAMP, a cAMP analog, may enhance the activity of C130026I21Rik by directly stimulating cAMP-dependent pathways that C130026I21Rik is involved in. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
This lipid signaling molecule may potentiate signaling pathways involving C130026I21Rik by acting through its specific G protein-coupled receptors to enhance downstream signaling. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Despite being a broad-spectrum kinase inhibitor, Staurosporine might selectively enhance pathways that involve C130026I21Rik by lifting the inhibition of certain kinases. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein inhibits tyrosine kinases, which may lead to an upregulation in signaling pathways that enhance the activity of C130026I21Rik by reducing competitive signaling interactions. | ||||||